PRP or Corticosteroid? Choosing Between Injection Therapies for Sports Injuries and Pain

Treatments for sports injuries continue to evolve, and injection therapy has become a popular option in recent years. The two therapies most often mentioned are platelet-rich plasma (PRP) and corticosteroid (steroid) injection. Although both are local injections, they differ substantially in mechanism, effect, and risk — and when treatment is needed more than once and has to be repeated, the interference and interaction between them deserve careful consideration. This article compares PRP and corticosteroid in depth across sports injuries such as tendinitis, ligament injury, muscle tears, and joint degeneration, to help readers understand the pros and cons of repeated injections and their clinical application.

Comparing the clinical effects of PRP and corticosteroid

For short-term pain relief, corticosteroid injection has a clear advantage: it can reduce inflammation quickly and ease pain within a few days. However, this effect is often short-lived; for chronic problems such as tennis elbow or knee degeneration, it usually lasts only a few weeks. By comparison, PRP works more slowly, but its medium- to long-term pain relief and functional improvement tend to be stable and durable, and it stands out especially at assessments three to six months later.

Beyond symptom control, PRP also has the ability to promote tissue healing. The growth factors it contains can stimulate regeneration of tendon, ligament, and even cartilage cells, repairing the injury at a more fundamental level. Corticosteroid, by contrast, does not have repair capacity, and with repeated injection may even lead to degeneration of soft-tissue structure and reduced tissue strength. So although both can provide pain relief, PRP has more potential to address the underlying problem.

In terms of treatment strategy, PRP is often given as a staged course, for example one injection every 2 to 4 weeks for a total of 2 to 4 injections to accumulate effect. Clinical studies suggest this pattern was associated with substantially better long-term outcomes than a single injection. Corticosteroid, on the other hand, is limited in frequency; for the same site a gap of at least 3 months between injections is generally suggested to avoid cumulative toxicity. Even so, repeated corticosteroid injections are still used in practice to control acute recurrent symptoms, but often with diminishing effect and increasing risk of side effects.

Some studies have explored the possibility of alternating or combining PRP and corticosteroid. For example, in patients with moderate arthritis, corticosteroid was given first to control early symptoms, followed by PRP to strengthen mid- to late-stage recovery. Short-term results were indeed better than either therapy alone, but at the 12-month comparison the PRP-only group and the combined group had similar effects. Other studies tried injecting PRP and corticosteroid at the same time and also observed improvements in pain and function scores. However, this kind of combined therapy is still exploratory and does not yet have clear clinical consensus behind it.

Biological mechanism differences at the cellular level

1. Corticosteroid inhibition of platelet function

Prednisolone, acting through the glucocorticoid receptor (GR), can inhibit platelet production of TXA₂ and cPLA₂ phosphorylation, thereby reducing platelet aggregation and activation. Long-term or high-dose corticosteroid can likewise weaken the survival and proliferation of bone marrow mesenchymal stem cells and chondrocytes, and induce cytotoxicity.

2. Corticosteroid suppression of growth factor release

Corticosteroid can, through GR/NF-κB cross-inhibition, suppress preosteoclast production of PDGF-BB, impairing angiogenesis and bone formation.

3. Cytoprotective effect of PRP growth factors

Multiple growth factors in PRP (such as TGF-β₁, PDGF-AB, IGF-I) can counteract corticosteroid toxicity to ligament and cartilage cells, promote cell proliferation, and reduce inflammatory markers.

PRP’s effect comes from platelets concentrated from your own blood. In the local tissue these platelets release large amounts of growth factors and cytokines, triggering the healing response, promoting cell proliferation, inducing angiogenesis, and increasing collagen synthesis. The whole process depends on a moderate and controlled inflammatory response to stimulate the body’s own repair mechanism.

Corticosteroid, by contrast, is a hormone that strongly suppresses inflammation. It can rapidly suppress the release of inflammatory mediators and leukocyte activity, achieving rapid reduction of swelling and pain. However, it also suppresses fibroblasts and collagen production, which is instead harmful to long-term tissue repair. Repeated injection may also cause tendon degeneration and chondrocyte apoptosis, speeding up joint degeneration.

These two very different mechanisms mean that using them at the same time may interfere with each other. Animal experiments and cell culture studies show that using PRP and corticosteroid together reduces PRP’s positive effect on cell proliferation and survival, and may even weaken PRP’s repair capacity. For this reason, prolotherapy in clinical practice never recommends mixing or combining corticosteroid, to avoid undoing the regenerative effect.

Some studies have also found that PRP itself has partial anti-inflammatory properties and, under certain conditions, can reduce corticosteroid toxicity to chondrocytes. So in some experiments, PRP could protect tissue from corticosteroid injury to a degree. However, this kind of two-way influence still needs more research to clarify, and the mainstream consensus currently is still that the two should be used in stages rather than at the same time.

Safety and side effects

In terms of side effects, PRP carries a relatively low overall risk because it is drawn from your own blood. The most common side effects are temporary pain and swelling at the injection site, which are usually part of the repair process. The infection risk is very low, and no serious immune reactions or tissue destruction have been reported. Even with multiple injections, PRP has not been shown to cause tissue degeneration, though the body’s inflammatory response after injection should be kept in mind, and some patients have short-term discomfort.

Corticosteroid injection is relatively more complex and carries more potential risks. Locally, it may cause skin atrophy, fat dimpling, pigment changes, and even an increased risk of tendon rupture from weakening of tissue structure. With intra-articular injection, repeated use may accelerate cartilage wear and narrowing of the joint space. Systemically, patients with diabetes may have a temporary rise in blood sugar after injection, and other uncommon but noteworthy reactions include adrenal suppression, facial flushing, and reduced immunity. So corticosteroid use requires particular care regarding frequency, dose, and injection site.

Effects and principles of repeated injection

Although corticosteroid has an irreplaceable rapid effect in the acute phase, in long-term treatment repeated injection may instead worsen joint degeneration. A maximum of 3 to 4 injections per year for the same joint is generally suggested, with each separated by several months or more. Many clinical observations also note that patients who rely on corticosteroid long-term to control symptoms may see their joint deteriorate even faster than those who did not receive it. So once treatment enters the stage of repeated injection, PRP is undoubtedly worth considering first.

Clinical practice and expert recommendations

According to international and domestic sports medicine expert opinion, PRP and corticosteroid are not recommended together or within a short interval of each other, because their mechanisms are highly conflicting. Relevant medical societies and studies have similar guidance that during PRP treatment corticosteroid medication should not be used, whether oral or injected. If a patient has recently had a corticosteroid injection, a gap of at least 4 to 6 weeks before PRP is generally suggested, to avoid residual drug effect interfering with the repair mechanism.

In actual practice, many physicians also ask patients not to have a corticosteroid injection for a month before PRP, and to avoid anti-inflammatory painkillers afterward, so as not to affect the outcome. On the guideline side, the American Academy of Orthopaedic Surgeons (AAOS) has long noted that the benefit of corticosteroid injection lasts only a few weeks and has adverse effects on cartilage, so it recommends conservative use. In contrast, PRP has shown medium- to long-term advantages in several randomized trials and has been increasingly used for chronic musculoskeletal conditions in clinical practice.

In summary, in both treatment strategy and long-term outcome, PRP appears clearly better than corticosteroid in safety, tissue protection, and regenerative potential in the populations studied. In application, if a patient is in an acute inflammatory phase, corticosteroid can serve as a bridging measure for pain relief, but it should not be used at the same time as PRP. Once the chronic phase begins, PRP should be prioritized as the main therapy, with adequate intervals and the correct sequence between treatments. Whether these treatments are appropriate for you depends on your condition and a physician’s assessment.